TABLE 1.

Patient characteristics

Patienta	Genderb	Age (yr)	Ethnicityc	HLA-A2	% of blood CD8+ T cells specific for HLA-A*0201-restricted peptidesd in:						CD4+ T cellse	Viral load (Copies/ml)e	Antiretroviral therapy
					HIV Gag		HIV Pol		CMV pp65
					PBMC	GALT	PBMC	GALT	PBMC	GALT
C01	M	23	H	+	0.00	0.00	ND	ND	0.33	0.20	ND
C02	F	40	C	+	0.00	0.00	0.00	0.00	0.02	0.00	ND
G01	M	54	C	−	0.02	ND	0.02	ND	0.01	ND	871	<50	Yes
G02	M	33	C	+	0.28	0.55	0.02	ND	1.06	0.09	394	72,000	No
G03	M	41	C	+	0.02	0.02	0.01	0.02	0.68	0.30	136	169,000	Yes
G04	F	46	C	+	0.69	1.20	0.85	1.00	2.02	0.18	170	260,000	No
G05	M	35	C	+	0.00	0.07	0.00	ND	3.53	0.27	417	13,017	No
G10	M	45	C	+	0.00	0.00	0.02	ND	1.22	0.07	235	8,000	No
G11	F	44	A	+	0.68	2.60	0.02	ND	0.15	0.02	324	5,130	No
G12	M	52	C	+	0.17	0.28	ND	ND	0.42	0.18	350	12,858	No
G13	M	37	A	+	1.53	0.57	0.02	ND	2.81	0.41	329	148,000	Yes (6 days)
G22	M	29	C	+	1.28	1.22	0.76	ND	0.05	0.03	ND	ND	No
G25	M	39	A, H	+	0.18	0.60	0.00	ND	0.13	0.04	671	45,378	Yes

^aC01 and C02 are HLA-A*0201-positive, HIV-negative controls. C01 is CMV seropositive, and C02 is CMV seronegative.

^bM, male; F, female.

^cC, Caucasian; A, African American; H, Hispanic or Latino.

^dAs determined by tetramer staining. Samples with a distinct tetramer binding population consisting of >0.03% CD8⁺ T cells were considered positive (see text).

^eCD4⁺ T-cell count and viral load were obtained from most recent clinic records.

^fND, not determined.